Published in J Int AIDS Soc on July 20, 2015
PrEP implementation: moving from trials to policy and practice. J Int AIDS Soc (2015) 0.86
Modeling and Cost-Effectiveness in HIV Prevention. Curr HIV/AIDS Rep (2016) 0.79
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Feasibility, Acceptability And Adherence With Short Term Hiv Pre-Exposure Prophylaxis In Female Sexual Partners Of Migrant Miners In Mozambique. J Acquir Immune Defic Syndr (2017) 0.75
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet (2014) 3.88
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Mathematical models in the evaluation of health programmes. Lancet (2011) 2.05
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS (2013) 1.81
Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology (2013) 1.54
Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet (2014) 1.49
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
The determinants of HIV treatment costs in resource limited settings. PLoS One (2012) 1.47
Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. AIDS (2013) 1.10
Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther (2012) 1.02
HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. PLoS Med (2012) 0.99
HIV prevalence and incidence in a cohort of women at higher risk for HIV acquisition in Chókwè, southern Mozambique. PLoS One (2014) 0.91
Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial. BMC Infect Dis (2012) 0.84
Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for? Expert Rev Pharmacoecon Outcomes Res (2014) 0.80
Population movements and the spread of HIV/AIDS in Mozambique. J Health Hum Serv Adm (2001) 0.78
Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One (2015) 0.79
Early HIV infection in the United States: a virus's eye view. PLoS Med (2013) 0.76
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS One (2016) 0.75
The Incidence Patterns Model to Estimate the Distribution of New HIV Infections in Sub-Saharan Africa: Development and Validation of a Mathematical Model. PLoS Med (2016) 0.75